E128: Nerandomilast for Autoimmune ILD (FIBRONEER-ILD)
About this episode
Covering a very interesting study this week, which investiaged the PDE4B inhibitor nerandomilast for patients with progressive pulmonary fibrosis (specifically including 325 patients with autoimmune ILD). Would have been yet another ho hum trial if not for the big reveal... have a listen to find out!
Article: https://www.nejm.org/doi/full/10.1056/NEJMoa2503643
Get every episode summarized
Each time The Evidence Based Rheumatology Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Evidence Based Rheumatology Podcast
E133: Obinutuzumab for SLE (ALLEGORY)
The Evidence Based Rheumatology Podcast
E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE)
The Evidence Based Rheumatology Podcast
E131: A Sham-Controlled Sham of a Trial: RESET-RA
The Evidence Based Rheumatology Podcast
E130: Telitacicept for SLE
The Evidence Based Rheumatology Podcast